# LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

> **NCT06232408** · PHASE1 · TERMINATED · sponsor: **Repare Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** RP-1664

## Key facts

- **NCT ID:** NCT06232408
- **Lead sponsor:** Repare Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-14
- **Primary completion:** 2025-08-27
- **Final completion:** 2025-08-27
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Sponsor decided to terminate study early
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232408, "LIONS (PLK4 Inhibitor in Advanced Solid Tumors)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06232408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*